April 24, 2025



DC Update: NASADAD Resource: The Substance Use Workforce Crisis Drivers, Challenges, and Promising Strategies, National Fentanyl Awareness Day: April 29, CDC Study on Routes of Cannabis Use, and More.



Visit our Website

Meet the Member

Kyle Devine, SSA for Nevada, Deputy Administrator for Regulatory and Planning Services, Division of Public and Behavioral Health, Nevada Department of Health and Human Services

Kyle Devine currently serves as Deputy Administrator for Regulatory and Planning Services at the Division of Public and Behavioral Health within the Nevada Department of Health and Human Services. He also serves as the Single State Agency (SSA) Director for Nevada.



Mr. Devine has over three decades of experience in building programs across Nevada and northeastern California, including over 20 years with the Division of Public and Behavioral Health. He first joined the Division as a Health Program Manager and later served as a Clinical Program Manager before most recently serving as Bureau Chief of the Division. In these roles, Mr. Devine was tasked with managing State programs concerning child and maternal health, mental health and substance use disorder (SUD), and chronic disease.


In his current capacity as Deputy Administrator, Mr. Devine oversees the Division of Public and Behavioral Health's Regulatory and Planning Services. Specifically, he is responsible for the regulation of health facilities, environmental health, emergency medical systems, radiation control, and SUD treatment and prevention. In addition, Mr. Devine manages the Office of Vital Records, Medical Marijuana Registry, the Primary Care Office, and planning activities for mental health and SUD and public health preparedness in Nevada.

Mr. Devine is a native Nevadan who acquired a Bachelor of Arts in Health Education from the University of Nevada, Reno and a master's in social work. He later graduated from the Great Basin Public Health Leadership Institute and has a green belt in LEAN/Six Sigma.

NASADAD News

NASADAD Resource: The Substance Use Workforce Crisis: Drivers, Challenges, and Promising Strategies

On April 22, NASADAD published a new issue brief on <u>The</u> <u>Substance Use Workforce Crisis: Drivers, Challenges, and</u> <u>Promising Strategies</u>. The brief explores the systemic issues fueling the substance use workforce shortage and innovative solutions being implemented across the country. Specifically, the brief presents actionable strategies to grow and sustain a skilled workforce and features real-world examples of these strategies being applied in States and communities across the nation to bolster recruitment, retention, and professional advancement. Further, the brief emphasizes that addressing workforce challenges requires a long-term, sustained



commitment, and calls for investments in comprehensive workforce development plans that reflect the essential role substance use professionals play across the continuum of care.

The brief can be downloaded in full, here.

State Alcohol and Drug Agency Leaders Meet with Dr. Nora Volkow at the Rx and Illicit Drug Summit

On April 22, State alcohol and drug agency leaders from Tennessee, Pennsylvania, Arkansas, Georgia, and Oregon met with Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), during the Rx and Illicit Drug Summit in Nashville, Tennessee.



Thank you, Dr. Volkow, for your partnership with NASADAD and States.



2025 National Prevention Network Conference- Early Bird Registration!

The 2025 *NASADAD National Prevention Network (NPN) Conference* will be held August 11-13, 2025, at the Grand Hyatt Washington, D.C. The NPN Conference highlights the latest research in the substance use prevention field and provides a forum for prevention professionals, coalition leaders, researchers, and federal partners to share research, best practices, and evaluation results for the purpose of integrating research into practice. This year's theme is: *Substance Use Prevention Across the Lifespan: Creating a Monumental Impact.*

Early bird registration is now open through May 16. Additional information can be found on the registration page <u>here</u>.

Around the Agencies

National Fentanyl Awareness Day: April 29!

Each year, April 29 is recognized as <u>National Fentanyl Awareness</u> <u>Day (NFAD)</u>. Now in its fourth year, NFAD is an annual observance dedicated to raising awareness of the dangers of illicitly-



manufactured fentanyl and counterfeit prescription pills, especially among youth. NFAD is supported by a coalition of experts, corporations, community groups, nonprofits, schools, families, and elected officials who unite to promote vital prevention strategies to prevent nonfatal and fatal overdoses. In recognition of NFAD, the *NFAD 2025 Toolkit* has been released, which contains various resources on the dangers of fentanyl, including fact sheets, social media graphics, and videos. The Toolkit can be downloaded in full, <u>here</u>.

The Centers for Disease Control and Prevention (CDC) also released a <u>National Fentanyl</u> <u>Awareness Day Toolkit</u> that offers key messages, sample social media graphics, and links to additional CDC resources on fentanyl.

SAMHSA Releases Updated 988 Partner Toolkit


The Substance Abuse and Mental Health Services Administration (SAMHSA) recently released an updated <u>988 Partner Toolkit</u>. The updated toolkit includes new 988-branded photography, print materials, banners, explainer videos, and user guides. Specifically, the new resources in the updated toolkit include:

- <u>988 Branded Photography</u>
- <u>988 Print Materials</u>
- <u>988 Judgment-Free Bus Stop Banner</u>
- What is 988 and How Does it Work?
- <u>988 & 911 Social Media Content</u>

The resources can be downloaded individually or as a whole on the SAMHSA store, here.

SAMHSA Resource: Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk

The Substance Abuse and Mental Health Services Administration (SAMHSA) released a Clinical Advisory on *Considerations for <u>Considerations for Genetic Testing in the</u> <u>Assessment of Substance Use Disorder Risk</u>. The Advisory examines the role of genetic testing in assessing patients' vulnerability to developing a substance use disorder (SUD) and discusses the limitations of the latest risk assessment testing technology. Key messages include:*



• "Substance use disorder risk reflects an interplay of genetic, environmental, and

psychosocial factors, highlighting the need for comprehensive, multidimensional risk screening and whole-person care.

- In the absence of appropriate clinical guidelines and safeguards to ensure responsible and equitable use, SAMHSA recommends against routine use of genetic testing as the sole indicator of substance use disorder risk in clinical practice.
- While genetic testing provides useful insights, it is potentially most effective when used alongside established tools to support multidimensional risk assessment.
- Privacy protections, informed consent, and careful implementation are essential to ensure genetic testing is used responsibly and equitably.
- Integrating genetic testing with validated tools and biopsychosocial evaluations ensures patient-centered care and informed clinical decisions.
- Ongoing research and clear guidelines are critical to responsibly incorporating genetic testing into SUD prevention and treatment."

The Advisory can be downloaded in full, here.

Legislative Analysis and Public Policy Association Publishes Model Building the Substance Use Disorder Workforce of the Future Act

The Legislative Analysis and Public Policy Association (LAPPA), funded by the White House Office of National Drug Control Policy (ONDCP), in collaboration with the O'Neill Institute for National and Global Heath Law at Georgetown University, published the <u>Model</u> <u>Building the Substance Use Disorder Workforce of the Future Act</u>. This Model Act is designed to address the shortage of professions for the substance use disorder (SUD) workforce, including psychiatrists, psychologists, addiction medicine specialists, addiction counselors, social workers, nursing professionals, peer support professionals, and others. Specifically, the Model Act provides guidance for States to adopt a strategy that supports immediate, intermediate, and long-term measures to build and sustain a SUD workforce.

The Model Act can be read in full, here.

Research Roundup

CDC Report on Routes of Marijuana Use in the United States, 2022

The Centers for Disease Control and Prevention (CDC) recently published a report in the *Morbidity and Mortality Weekly Report* (*MMWR*) on <u>Routes of Marijuana Use – Behavioral Risk Factor</u> <u>Surveillance System, 22 U.S. States and Two Territories, 2022</u>.



The report analyzed data from the *2022 Behavioral Risk Factor Surveillance System*, which included an optional marijuana module for the first time, of 22 States and two US territories that administered the optional marijuana module to determine routes of marijuana use among adults in the US. Specifically, the report found that, in 2022, 15.3% of adults reported current cannabis use, with 79.4% of them reporting smoking as the most frequent route of use. Other key findings include:

- "The study population comprised 138,625 respondents, including 14,044 (15.3%) who reported current marijuana use, and 6,848 (7.9%) who reported daily use.
 - Both current and daily marijuana use were most prevalent among adults aged 18–24 years (25.9% and 13.4%, respectively), males (18.0% and 9.5%, respectively), non-Hispanic multiracial adults (24.7% and 14.0%, respectively), Al/AN adults (20.7% and 14.0%, respectively), those with a high school diploma or less (17.2%–17.4% and 10.1%–12.1%, respectively), and women who were not pregnant (19.5% and 10.1%, respectively).
- Among adults who reported current cannabis use, smoking was the most prevalent route of use (79.4%), followed by eating (41.6%), vaping (30.3%), and dabbing (14.6%).
 - Vaping and dabbing were most prevalent among adults aged 18–24 years (44.7% and 28.4%, respectively) and among NH/PI adults (51.7% and 42,9%,

- respectively). Dabbing was also more prevalent among Al/AN adults (29.3%), and adults with less than a high school diploma (23.0%).
- Approximately one half of adults who currently use cannabis reported two or more routes of use (46.7%).
 - Among adults who reported current cannabis use and two or more routes of use, the most prevalent combinations were smoking and eating (55.2%) and smoking and vaping (54.5%)."

The report calls for heightened surveillance of routes of cannabis use and use patterns to inform cannabis use prevention and treatment policies as the cannabis market continues to evolve.

The report can be downloaded in full, here.

Webinars to Watch

National Fentanyl Awareness Day Webinar: The New Drug Talk: Community Edition Virtual Screening

In recognition of National Fentanyl Awareness Day, *Song for Charlie* is hosting a webinar on *The New Drug Talk: Community Edition Virtual Screening*. This no-cost webinar is on April 29, at 3:00 pm ET. The webinar will include a screening of a 27-minute-long film for parents and communities about protecting youth from illicitly-manufactured fentanyl and counterfeit prescription pills, followed by a discussion featuring a panel of impacted family members, medical professionals, and prevention experts. Learning objectives include:

- "The current reality of fentanyl and fake prescription pills
- How to have effective conversations with teens and young adults
- Warning signs to look for and actions to take
- Where to find naloxone and how to use it
- How companies can support employees in protecting the young people in their lives."

Registration is required.

NAADAC Webinar: Redefining Recovery: Insights into Gambling and Substance Use Disorders



NAADAC, the Association for Addiction Professionals, is hosting a webinar on *Redefining Recovery: Insights into Gambling and*

<u>Substance Use Disorders</u>. This no-cost webinar is on May 7, at 12:00 pm ET. The webinar is intended for addiction professionals and will give an overview of trends in recovery dynamics and best practices regarding recovery-focused care to address gambling and substance use disorder (SUD). Specifically, the webinar will reevaluate conventional recovery frameworks to account for the relationship between gambling and substance use, including comparing their recovery trajectories and discussing specific interventions to address both conditions, using case studies of strategies being implemented across the country. Learning objectives include:

- "Participants will be able to analyze emerging trends and best practices in recoveryoriented care for gambling and substance use disorders, emphasizing holistic approaches that integrate psychological, social, and environmental factors.
- Participants will be able to identify key barriers to recovery faced by individuals with co-occurring gambling and substance use disorders, such as social stigma, relapse triggers, and comorbid mental health conditions.
- Participants will be able to utilize skills to create a more inclusive and supportive treatment environment for individuals affected by gambling and substance use disorders, fostering a culture of recovery that transcends traditional boundaries."

Participation in this webinar is eligible for 1.5 Continuing Education (CE) Hours.

Registration is required.

NASADAD | 1919 Pennsylvania Avenue NW Suite M 250 | Washington, DC 20006 US

Unsubscribe | Update Profile | Constant Contact Data Notice



Try email marketing for free today!